In a report released on July 30, Nicolas Pauillac from Kepler Capital maintained a Hold rating on GlaxoSmithKline, with a price target of p1,500.00. The company’s shares closed yesterday at p1,418.00.

Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline today and set a price target of £13.97. The company’s shares opened today at p1,424.50. Take advantage of TipRanks Premium ...

GlaxoSmithKline Pharmaceuticals to launch oncology assets Jemperli and Zejula in India, addressing critical unmet needs in ...

GlaxoSmithKline Pharmaceuticals on Friday said its consolidated net profit increased 12 per cent year-on-year to Rs 279 crore ...

GlaxoSmithKline Pharmaceuticals reports a 12% increase in net profit to Rs 279 crore for the June quarter despite a slight ...

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its ...

GLAXOSMITHKLINE PHARMACEUTICALS LTD - Clarification sought from GlaxoSmithKline Pharmaceuticals Ltd - Rediff MoneyWiz, the personal finance service from Rediff.com equips the user with tools and ...

Health Sanofi, GlaxoSmithKline set to start Phase 3 trials for COVID-19 vaccine after earlier setback In December, companies said early trials showed 'insufficient' immune response in older adults ...

Canada has had a deal with GlaxoSmithKline for influenza vaccines since 2001. The new agreement, which took effect July 1, was announced at GSK Canada in Quebec City, which employs 900 people.